

Glenholme Senior Living (Sheffield) Ltd
Co. No. 10015774


GLENHOLME HEALTHCARE GROUP LIMITED

FINANCIAL STATEMENTS

31 MARCH 2023

See note 25 on page 30
with reference to the guarantee
under s479(A) of the Companies Act

Glenholme
Group



GLENHOLME HEALTHCARE GROUP LIMITED

FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

CONTENTS	PAGE
Officers and professional advisers	1
Strategic report	2 - 4
Directors' report	5 - 7
Independent auditor's report to the shareholders	8 - 10
Group statement of comprehensive income	11
Group and company statement of financial position	12
Group and company statement of changes in equity	13
Group cash flow statement	14
Notes to the financial statements	15 - 30

GLENHOLME HEALTHCARE GROUP LIMITED

OFFICERS AND PROFESSIONAL ADVISERS

THE BOARD OF DIRECTORS

Lord P R Carter
K W Phippen
D R Baty
D M Serratt
G P Macalister
A B Washburn
S J McLaughlan
E Bannister

COMPANY SECRETARY

S J McLaughlan

REGISTERED OFFICE

Sun House
79 High Street
Eton
Berkshire
SL4 6AF

AUDITOR

Kingly Jones LLP
Registered Auditors
Chartered Accountants
414 Linen Hall
162 – 168 Regent Street
London
W1B 5TE

GLENHOLME HEALTHCARE GROUP LIMITED

STRATEGIC REPORT

YEAR ENDED 31 MARCH 2023

The directors have pleasure in presenting their strategic report for the year to 31 March 2023.

PRINCIPAL ACTIVITIES AND BUSINESS REVIEW

The principal activity of the group during the year was the provision of nursing, residential and supported living services for the elderly and those with learning disabilities, autism, physical disabilities and mental health issues. In addition the group is involved in property rental.

It is the intention of the group to continue the organic expansion of its nursing, residential and supported living services for adults as opportunities present themselves. In addition, the Board will also consider potential strategic acquisitions which enhance the existing portfolio.

The group has the following operating units in place at year end:

Nursing and Residential beds for Elderly individuals 225 Beds (2022: 167)

Residential units for younger adults 49 units (2022: 49 units)

Supported living for younger adults 94 units (2022: 99 units)

During the year, the group commissioned the following new service.

58 bed care home in Horncastle, Lincs.

In addition, a new Brighton home (additional 5 support living places) is due to be completed in June 2023. The group has started the construction of a 56-bed home in March in Cambridgeshire, which is projected to be completed in early 2024, and a 6 bed challenging behaviour unit and 13 flats for learning disabilities in Lincolnshire which should be completed in later part of 2024. The group intends to purchase a further house in Brighton, and another flat in Stevenage for Learning and Physical Disabilities service which should be ready for opening later in 2023.

More information about the group can be found on the group website, www.glenholme.org.uk.

The group has a number of maturing services. As always new services take time to reach maturity and the financial performance of these new services has yet to be reflected in the operating results for this year. The Directors look towards the next financial year with optimism.

The directors look forward to working with the local communities to help best meet the needs of their residents.

During the year end the group completed a £19m development finance loan with Santander and drawdown £2m of the £4.4m loan with Triodos in the year. These funds will be allocated to projects that meet the group's expansion strategy.

The group's strategy has not changed in the year.

GLENHOLME HEALTHCARE GROUP LIMITED

STRATEGIC REPORT

YEAR ENDED 31 MARCH 2023

KEY PERFORMANCE INDICATORS

The group monitors its performance against strategic objectives by means of key performance indicators. The main KPIs it uses are orientated around gross profit margin and turnover. These are summarised thus:

	2023	2022
	£	£
Turnover	21,731,395	17,848,140
Gross profit %	20%	27%
EBITDA (excluding revaluations)	2,576,649	3,228,149
Number of employees	775	532
Net assets	29,797,442	26,789,820
Residential beds	276	216
Residential occupancy %	61%	60%
Supported Living service users	75	66
Rental yield	3.2%	3.2%

PRINCIPAL RISKS AND UNCERTAINTIES

The principal risks and uncertainties faced by the group are common for a group of this size. These are:

- (a) Virus impact on both staff and residents
- (b) Deterioration in quality of care and support.
- (c) Difficult relationships with the relevant regulatory agencies.
- (d) Maintaining working capital sufficient to meet the needs of the group.
- (e) Miscalculating risk associated with new acquisition and new development project.
- (f) Retention and recruitment of staff for all skill levels required to maintain high levels of care.
- (g) Differential inflation caused by inflationary pressures in cost base not being matched by longer term contracts.

The group has successfully controlled and managed these risks by:

- (a) Stringent infection control procedures and staff isolation.
- (b) Policy for all staff to be vaccinated in accordance with government guidance.
- (c) Internal Quality Audits.
- (d) Staff training and development program.
- (e) Regular service user, staff and relative surveys.
- (f) Recruitment of foreign staff through the government's sponsorship scheme.
- (g) Continued evaluation of the cash flow needs of the Group.
- (h) Board level due diligence relating to ongoing operations and potential development activity.

GLENHOLME HEALTHCARE GROUP LIMITED

STRATEGIC REPORT

YEAR ENDED 31 MARCH 2023

SECTION 172(1) STATEMENT

The directors confirm that they have acted in good faith in the way they consider what would be most likely to promote the success of the company for the benefit of its members as a whole. In doing so they have considered, among other matters, those set out in section 172(1) (a) to (f) of the Companies Act 2006

- a) the likely consequence of any decision in the long term;
- b) the interests of the group's employees;
- c) the need to foster the group's business relationships with suppliers, customers and others;
- d) the impact on the group's operations on the community and the environment;
- e) the desirability of the group maintain a reputation for high standards of business conduct; and
- f) the need to act fairly as between the members of the company.

The directors consider the primary stakeholders in these regards as its employees and customers. Engagement with all stakeholders is of fundamental importance across the business and the directors are focused on building these relationships on a continuous basis.

Employees

The employees are at the centre of group activities and the group continues to invest time and money in making Glenholme a better place to work. The directors recognise the success of the business depends on attracting, retaining and motivating employees, by ensuring that group remains a responsible employer, from pay and benefits to the health, safety and workplace environment.

Customers

The care and wellbeing of Glenholme's customers is its greatest priority.

The directors consider that in the best interests of the group and to do the right thing in terms of delivering continued value for all stakeholders, over the long term that cash be retained to continue investment to further develop and grow the business. Continual investment in new services will have the beneficial impact on the community providing quality jobs and supporting the development of a low carbon infrastructure by working to minimise emissions.

FUTURE DEVELOPMENTS

The group expects to improve its financial performance by a policy of controlled growth and acquisitions.

Approved by the directors on 31st July 2023 and signed on their behalf by:


K W Phippen
Managing Director

GLENHOLME HEALTHCARE GROUP LIMITED

DIRECTORS' REPORT *continued*

YEAR ENDED 31 MARCH 2023

DIRECTORS' RESPONSIBILITIES *continued*

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group's and company's transactions and disclose with reasonable accuracy at any time the financial position of the company and group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STEAMLINED ENERGY AND CARBON REPORTING (SECR)

	Unit	2023	2022
Emissions resulting from activities for which the group is responsible	tCO ₂ e	726	648
Emissions reduced through net zero fuel sourcing	tCO ₂ e	(54)	(51)
Emissions resulting from purchase of electricity by the Group for its own use	tCO ₂ e	227	202
Emissions resulting from activities for which the group is responsible	tCO ₂ e	-	-
Total emissions	tCO ₂ e	899	799
Total energy consumption	kwh	<u>4,379,321</u>	<u>3,893,098</u>
Intensity ratio (Scope 1, Scope 2 and Scope 3 emissions per £100k of turnover)		<u>4.14</u>	<u>4.48</u>

Methodologies for energy and emission calculations

The directors have followed the 2019 HM Government Reporting Guidelines. They have used the GHG Reporting Protocol Corporate Standard.

Principal measures to increase energy efficiency

The group's energy consumption, in kilowatt hours, associated greenhouse gas (GHG) emissions, in tonnes of carbon dioxide equivalent (tCO₂e) and additional related information for the year ended 31st March 2023 is set out above.

The group will continue to monitor performance against the target of reducing all intensity ratios across the group.

GLENHOLME HEALTHCARE GROUP LIMITED

DIRECTORS' REPORT *continued*

YEAR ENDED 31 MARCH 2023

STRATEGIC REPORT

The group has chosen in accordance with Section 414C(11) of the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 to set out within the group's Strategic Report the Company's Strategic Report Information Required by Schedule 7 of the Large and Medium Sized Companies and Groups (Accounts and Reports) Regulation 2008. This includes information that would have been included in the business review and details of the principal risks and uncertainties.

AUDITOR


Kingly Jones LLP are deemed to be re-appointed under section 487(2) of the Companies Act 2006.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

Each of the persons who is a director at the date of approval of this report confirm that:

- so far as each director is aware, there is no relevant audit information of which the company's auditor is unaware; and
- each director has taken all steps that they ought to have taken as a director to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

Approved by the directors on 31st July 2023 and signed on their behalf by:



S J McLaughlan
Company Secretary

Registered office:
79 High Street
Eton
Windsor
Berkshire
SL4 6AF

GLENHOLME HEALTHCARE GROUP LIMITED

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF GLENHOLME HEALTHCARE GROUP LIMITED

YEAR ENDED 31 MARCH 2023

Opinion

We have audited the financial statements of Glenholme Healthcare Group Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 March 2023 which comprise the Group Statement of Comprehensive Income, Group Statement of Other Comprehensive Income, Group Balance Sheet, Company Balance Sheet, Group and Company Statement of Changes in Equity, Group Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and of the parent company affairs as at 31 March 2023, and of the group's profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF GLENHOLME HEALTHCARE GROUP LIMITED

YEAR ENDED 31 MARCH 2023

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Directors has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on pages 5 and 6, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the group and parent, we identified the principal risks of non-compliance with laws and regulations and considered the extent to which non-compliance might have a material effect on the financial statements. We determined the most relevant to be specific assertions in the financial statements such as the Companies Act 2006, tax regulation and the Financial Reporting Standard applicable to the UK (FRS102).

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF GLENHOLME HEALTHCARE GROUP LIMITED

YEAR ENDED 31 MARCH 2023

We assessed the susceptibility of the group and company's financial statements to material misstatement and how fraud might occur, including discussion with the directors, discussion with the audit team at the planning stage. We determined the principal risks were related to posting journal entries to manipulate profit, and management bias in accounting estimates.

To address the risk fraud through management bias and override of controls, we:

- Performed analytical procedures to identify any unusual or unexpected relationships.
- Identified and tested journal entries identified any significant transactions that were unusual or outside the normal cause of business.
- Challenged assumptions and judgements made by management in determining significant accounting estimates.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed audit procedures which included, but not limited to:


- Agreeing financial statements disclosure to underlying supporting documentation.
- Discussion with management of known instances of non-compliance with laws and regulations.
- Reviewing relevant Board minutes.

There are inherent limitations in the audit procedures above, we are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to transactions effected in the financial statements or us not detecting a material misstatement due to fraud, as fraud may involve deliberate concealment by misrepresentation or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorresponsibilities. This description forms part of our Report of the Auditors.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Martin Jones (Senior Statutory Auditor)
for and on behalf of Kingly Jones LLP
Chartered Accountants
Statutory Auditors
414 Linen Hall
162-168 Regent Street
London
W1B 5TE

31st July 2023

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

GROUP STATEMENT OF COMPREHENSIVE INCOME

YEAR ENDED 31 MARCH 2023

	Notes	2023 £	2022 £
GROUP TURNOVER	3	21,731,395	17,848,140
Cost of sales		(17,397,305)	(13,008,033)
GROSS PROFIT		4,334,090	4,840,107
Administrative expenses		(2,609,051)	(2,284,424)
Gain on revaluation of investment properties		1,850,000	41,329
Change in value of the joint venture company		57,553	450,200
OPERATING PROFIT	4	3,632,592	3,047,212
Interest payable and similar charges	7	(1,618,411)	(1,049,387)
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION		2,014,181	1,997,825
Tax on profit on ordinary activities	9	(588,846)	(664,093)
PROFIT ATTRIBUTABLE TO MEMBERS OF THE PARENT COMPANY		<u>1,425,335</u>	<u>1,333,732</u>
OTHER COMPREHENSIVE INCOME FOR THE YEAR			
Revaluation of freehold property less deferred tax		1,582,287	344,307
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		<u>3,007,622</u>	<u>1,678,039</u>

The company has taken advantage of section 408 of the Companies Act 2006 not to publish its own Profit and Loss Account.

All activities of the Group are from continuing operations.

The notes on pages 15 to 30 form part of these financial statements.

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

STATEMENT OF FINANCIAL POSITION

31 MARCH 2023

	Notes	2023 £	Group 2022 £	2023 £	Company 2022 £
FIXED ASSETS					
Tangible assets	12	61,562,549	50,676,886	87,047	66,913
Investments	13	554,552	487,700	3,973,632	3,906,680
		<u>62,117,101</u>	<u>51,164,586</u>	<u>4,060,679</u>	<u>3,973,593</u>
CURRENT ASSETS					
Stocks	14	20,288	10,739	-	-
Debtors amounts falling due within one year	15	3,369,544	2,887,706	18,595,321	13,921,208
Debtors amounts falling due after one year	15	387,833	270,289	8,702,973	8,541,064
Cash at bank and in hand		1,576,001	4,413,019	911,324	3,341,935
		<u>5,353,666</u>	<u>7,581,753</u>	<u>28,209,618</u>	<u>25,804,207</u>
CREDITORS: Amounts falling due within one year	16	<u>(5,670,569)</u>	<u>(4,842,830)</u>	<u>(14,869,818)</u>	<u>(12,819,497)</u>
NET CURRENT ASSETS / (LIABILITIES)		<u>(316,903)</u>	<u>2,738,923</u>	<u>13,339,800</u>	<u>12,984,710</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>61,800,198</u>	<u>53,903,509</u>	<u>17,400,479</u>	<u>16,958,303</u>
CREDITORS: Amounts falling due after more than one year	17	<u>(28,352,262)</u>	<u>(24,520,982)</u>	<u>(1,550,565)</u>	<u>(1,556,758)</u>
PROVISIONS FOR LIABILITIES					
Deferred taxation	18	<u>(3,650,494)</u>	<u>(2,592,707)</u>	-	-
		<u>29,797,442</u>	<u>26,789,820</u>	<u>15,849,914</u>	<u>15,401,545</u>
CAPITAL AND RESERVES					
Called-up equity share capital	19	246	246	246	246
Share premium account	20	11,480,232	11,480,232	11,480,232	11,480,232
Revaluation reserve	20	10,987,847	8,035,148	-	-
Profit and loss account b/f				3,921,067	3,937,068
Profit/Loss for the year				448,369	(16,001)
Profit and loss account	20	7,329,092	7,274,169	4,369,436	3,921,067
		<u>29,797,417</u>	<u>26,789,795</u>	<u>15,849,914</u>	<u>15,401,545</u>
Minority Interest		25	25	-	-
SHAREHOLDERS' FUNDS		<u>29,797,442</u>	<u>26,789,820</u>	<u>15,849,914</u>	<u>15,401,545</u>

These accounts were approved by the directors and authorised for issue on 31st July 2023, and are signed on their behalf by:



S J McLaughlan
Financial Director

Company Registration Number: 07681646

The notes on pages 15 to 30 form part of these financial statements.

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

STATEMENT OF CHANGES IN EQUITY

31 MARCH 2023

GROUP

	Called up share capital	Share Premium	Revaluation Reserve	Profit and Loss account	Share holders funds
	£	£	£	£	£
At 1 April 2021	246	11,480,232	7,863,617	5,767,661	25,111,756
Profit for the financial year	-	-	-	1,333,732	1,333,732
Revaluation of tangible fixed assets			344,307		344,307
Reclassification from revaluation reserve to profit and loss account	-	-	(172,776)	172,776	-
At 31 March 2022	246	11,480,232	8,035,148	7,274,169	26,789,795
Profit for the financial year	-	-	-	1,425,335	1,425,335
Revaluation of freehold property less deferred tax	-	-	1,582,287	-	1,582,287
Reclassification from revaluation reserve to profit and loss account	-	-	1,370,412	(1,370,412)	-
At 31 March 2023	246	11,480,232	10,987,847	7,329,092	29,797,417

The revaluation reserve is not distributable.

COMPANY

	Called up share capital	Share Premium	Revaluation Reserve	Profit and Loss account	Share- holders funds
	£	£	£	£	£
At 1 April 2021	246	11,480,232	-	3,937,068	15,417,546
Profit for the financial year	-	-	-	(16,001)	(16,001)
At 31 March 2022	246	11,480,232	-	3,921,067	15,401,545
Profit for the financial year	-	-	-	448,369	448,369
At 31 March 2023	246	11,480,232	-	4,369,436	15,849,914

The notes on pages 15 to 30 form part of these financial statements.

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

GROUP CASH FLOW STATEMENT

YEAR ENDED 31 MARCH 2023

	2022	2021
£	£	£
CASH INFLOW FROM OPERATING ACTIVITIES		
Profit for the financial year	1,425,335	1,333,732
<i>Adjustments for:</i>		
Revaluation of investment properties	(1,850,000)	(41,329)
Revaluation of joint venture company	(57,553)	(450,200)
Depreciation of tangible assets	851,610	672,466
Profit on disposal	(1,037)	(133)
Interest payable and similar charges	1,618,411	1,049,387
Tax on profit on ordinary activities	588,846	664,093
<i>Changes in:</i>		
Stocks	(9,549)	453
Trade and other debtors	(659,940)	31,141
Trade and other creditors	836,700	(994,158)
CASH GENERATED FROM OPERATIONS	2,742,823	2,265,452
Income taxes paid	-	-
NET CASH GENERATED FROM OPERATING ACTIVITIES	2,742,823	2,265,452
CASH FLOWS FROM INVESTING ACTIVITIES		
Payments to acquire tangible fixed assets	(7,836,045)	(3,836,658)
Minority interest	-	25
Investment in related company	(9,299)	-
Proceeds of disposals	1,037	2,975
	(7,844,307)	(3,833,658)
CASH FLOWS FROM FINANCING ACTIVITIES		
New bank loans	4,048,750	6,000,000
Repayment of bank loans	(216,653)	(1,059,882)
Loan to director	-	(175,000)
Repayment of directors' loan	17,417	4,750
Capital element of hire purchase	(9,780)	(3,458)
Interest paid	(1,618,411)	(1,049,387)
Net movement in related company loan	43,143	593,798
	2,264,466	4,310,821
NET (DECREASE) / INCREASE IN CASH EQUIVALENTS	(2,837,018)	2,742,615
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	4,413,019	1,670,404
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	1,576,001	4,413,019

The notes on page 15 to 30 form part of these financial statements.

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

1. STATEMENT OF COMPLIANCE AND COMPANY INFORMATION

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'. The company has taken advantage of section 408 of the Companies Act 2006 not to publish its own Profit and Loss Account.

Glenholme Healthcare Group Limited is private company limited by shares and is incorporated & domiciled in England, United Kingdom under the Companies Act 2006. The address of its registered office and principal place of business are disclosed on page 1.

2. ACCOUNTING POLICIES

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

There are no material judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

The Group owns most of its properties and as such is subject to the movement of the property market.

Basis of consolidation

The consolidated financial statements incorporate the financial statements of the company and all group undertakings. These are adjusted, where appropriate, to conform to group accounting policies. Acquisitions are accounted for under the acquisition method and goodwill on consolidation is capitalised and written off over five years from the year of acquisition. The results of companies acquired or disposed of are included in the group profit and loss account after or up to the date that control passes respectively. As a consolidated group profit and loss account is published, a separate profit and loss account for the parent company is omitted from the group financial statements by virtue of section 408 of the Companies Act 2006.

Revenue recognition

Turnover is measured as the fair value of the consideration received or receivable for care provided, rents receivable and goods supplied, net of discounts and Value Added Tax where applicable.

Revenue from the rendering of services is measured by reference to the stage of completion of the service transaction at the end of the reporting period provided that the outcome can be reliably estimated. When the outcome cannot be reliably estimated, revenue is recognised only to the extent that expenses recognised are recoverable.

Current and deferred tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

2. ACCOUNTING POLICIES (continued)

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Deferred tax has been recognised on all property revaluations as if the properties were sold at their revalued amount, the associated tax charge / credit has been charged to the revaluation reserve.

Intangible assets

Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at revalued amounts, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses.

Intangible assets acquired as part of a business combination are recorded at the fair value at the acquisition date.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

Goodwill	-	5 years straight line
----------	---	-----------------------

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

Investment properties

Investment properties are initially recorded at cost, which includes purchase price and any directly attributable expenditure.

Investment properties are revalued to their fair value at each reporting date and any changes in fair value are recognised in profit or loss. Investment properties are not depreciated because of this revaluation process.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Freehold property	-	2% on cost
Freehold land	-	is not depreciated
Fixtures fittings & equipment	-	20% to 33% on cost
Motor vehicles	-	20% on cost

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

2. ACCOUNTING POLICIES (continued)

Investments

Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.

Associates and joint ventures

An entity is treated as a joint venture where the Group is a party to a contractual agreement with one or more parties from outside the Group to undertake an economic activity that is subject to joint control. An entity is treated as an associated undertaking where the Group exercises significant influence in that it has the power to participate in the operating and financial policy decisions. In the consolidated accounts, interests in associated undertakings are accounted for using the equity method of accounting. Under this method an equity investment is initially recognised at the transaction price (including transaction costs) and is subsequently adjusted to reflect the investors share of the profit or loss, other comprehensive income and equity of the associate. The Consolidated statement of comprehensive income includes the Group's share of the operating results, interest, pre-tax results and attributable taxation of such undertakings applying accounting policies consistent with those of the Group. In the Consolidated statement of financial position, the interests in associated undertakings are shown as the Group's share of the identifiable net assets, including any unamortised premium paid on acquisition.

Any premium on acquisition is dealt with in accordance with the goodwill policy.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.

Hire purchase agreements

Assets held under hire purchase agreements are capitalised and disclosed under tangible fixed assets at their fair value. The capital element of the future payments is treated as a liability and the interest is charged to the group profit and loss account on a straight-line basis.

Operating lease agreements

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged against profits on a straight-line basis over the period of the lease.

Pension costs

The company operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the company. The annual contributions payable are charged to the group profit and loss account as incurred.

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

3. TURNOVER

The turnover and profit before tax are attributable to the provision of care to Glenholme's client group and rents receivable from associated properties. The directors regard these activities as one principal activity and arose solely in United Kingdom.

4. OPERATING PROFIT

Operating profit is stated after charging:

	2023 £	2022 £
Depreciation of owned fixed assets	851,610	672,466
Revaluation in the year of investment properties	1,850,000	41,329
Auditor's remuneration		
- as auditor of the group	16,080	12,450
- other professional services	-	10,500
Operating lease costs - property	36,000	36,000

5. PARTICULARS OF EMPLOYEES

The average number of staff employed by the group during the financial year amounted to:

	2023 No	2022 No
Average number of staff:		
Group	775	532
Company	33	24

The aggregate payroll costs of the above were:

	Group		Company	
	2023 £	2022 £	2023 £	2022 £
Wages and salaries	13,760,663	10,731,959	1,489,601	1,480,364
Social security costs	1,026,176	803,495	176,193	159,410
Other pension costs	362,506	282,326	57,495	53,753
	15,149,345	11,817,780	1,723,289	1,693,527

6. DIRECTORS' REMUNERATION

The directors' aggregate remuneration in respect of qualifying services were:

	2023 £	2022 £
Salaries	795,933	733,003
Pension contributions	79,945	44,984
Benefits in kind	7,597	7,099
Aggregate remuneration	883,475	785,086

The highest paid director received remuneration of £269,487 (2022: £274,867) The number of directors who accrued benefits under company pension schemes was as follows:

	2023 No	2022 No
Money purchase schemes	5	4

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

7. INTEREST PAYABLE AND SIMILAR CHARGES

	2023 £	2022 £
Interest payable on bank borrowing	1,461,585	893,907
Hire purchase interest	1,752	424
Other similar charges payable	155,074	155,056
	<u>1,618,411</u>	<u>1,049,387</u>

8. DIVIDENDS

There was no dividend payable in 2023 or 2022.

9. TAXATION ON ORDINARY ACTIVITIES

(a) Analysis of charge in the year

	2023 £	2022 £
Current tax:		
In respect of the year:		
UK Corporation tax based on the results for the year at 19% (2022 - 19%)	-	-
(Over)/under provision in prior year	-	-
Total current tax	-	-
Deferred tax (provided at 25% (2022 - 25%)):		
Origination and reversal of timing differences	740,884	693,472
(Over)/under provision in prior year	(152,038)	(29,379)
	<u>588,846</u>	<u>664,093</u>
Tax on profit on ordinary activities	<u>588,846</u>	<u>664,093</u>

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

9. TAXATION ON ORDINARY ACTIVITIES (continued)

(b) Factors affecting current tax charge

The tax assessed on the profit on ordinary activities for the year is lower than the standard rate of corporation tax in the UK of 19% (2022 - 19%).

	2023 £	2022 £
Profit on ordinary activities before taxation	<u>2,014,181</u>	<u>1,997,825</u>
Profit on ordinary activities at 19% (2022: 19%)	382,694	379,587
Expenses not deductible for tax purposes	3,064	2,231
Depreciation on non eligible assets	16,644	33,724
Other timing differences	38,000	-
Revaluation of investment	(10,935)	(85,538)
Leasing adjustment	50	-
Effect of change of rate on deferred tax to 25%	159,329	363,468
Prior year adjustment	-	(29,379)
Total tax (note 9 (a))	<u>588,846</u>	<u>664,093</u>

10. PROFIT ATTRIBUTABLE TO MEMBERS OF THE PARENT COMPANY

The profit dealt with in the financial statements of the parent company was £448,369 (2022: loss of £16,001).

11. INTANGIBLE FIXED ASSETS

Group	Goodwill £
COST	
At 1 April 2022 and 31 st March 2023	<u>2,478,097</u>
AMORTISATION	
At 1 April 2022 and 31 st March 2023	<u>2,478,097</u>
NET BOOK VALUE	
At 31 March 2023	<u>-</u>
At 31 March 2022	<u>-</u>

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

12. TANGIBLE FIXED ASSETS

Group	Freehold Properties £	Investment Properties £	Fixtures, Fittings & Equipment £	Motor Vehicles £	Total £
COST OR VALUATION					
At 1 April 2022	29,051,586	20,788,156	1,849,624	333,142	52,022,508
Additions	6,186,696	853,544	712,664	83,141	7,836,045
Revaluation	1,915,917	1,850,000			3,765,917
Disposals	-	-	(291,041)	(29,200)	(320,241)
At 31 March 2023	37,154,199	23,491,700	2,271,247	387,083	63,304,229
DEPRECIATION					
At 1 April 2022	165,669	-	1,010,720	169,233	1,345,622
Charge for the year	378,559	-	413,058	59,993	851,610
Revaluation	(135,311)	-	-	-	(135,311)
Disposals	-	-	(291,041)	(29,200)	(320,241)
At 31 March 2023	408,917	-	1,132,737	200,026	1,741,680
NET BOOK VALUE					
At 31 March 2023	36,745,282	23,491,700	1,138,510	187,057	61,562,549
At 31 March 2022	28,885,917	20,788,156	838,904	163,909	50,676,886

Included in Freehold Properties is £1,702,120 (2022: £3,221,606) of assets in the course of construction.

Assets held under hire purchase agreements for both the group and the company, included in motor vehicles were as follows:

	2023 £	2022 £
Cost	-	17,799
Accumulated depreciation	-	(8,716)
At 31 March	-	9,083
Depreciation charge	-	3,564

The freehold properties in Finchley and Haddon House in Peterborough and the investment properties in Hemel Hempstead, Crown Mews in Peterborough, Hightrees in Enfield, Warwick Manor and Shakespeare in Bedford and the leasehold investment properties in Stevenage were valued by Eddisons Taylor, Chartered Surveyors on 25th February 2022 on an open market value basis. The Directors after reviewing the principal assumptions believe the valuation value is still appropriate as at the year end.

The freehold property in Sleaford known as Holdingham Lodge was valued on completion by Eddisons Taylor, Chartered Surveyors on 23rd September 2021. The Directors after reviewing the principal assumptions believe the valuation value is still appropriate as at the year end.

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

12. TANGIBLE FIXED ASSETS (continued)

The freehold property in Sleaford known as Holdingham House and Grange were valued by Knight Frank, Chartered Surveyors on 14th February 2023. The Directors after reviewing the principal assumptions believe the valuation is not materially different to the value as at the year end.

The freehold property in Ely in Cambridgeshire, known as Vera James House was valued by Knight Frank, Chartered Surveyors on 8th January 2020. The Directors after reviewing the principal assumptions believe the valuation is not materially different to the value as at the year end.

The freehold investment properties in Brighton and Byfleet were valued by Eddisons Taylor, Chartered Surveyors on the 1st December 2022 on an existing use open market basis. The Directors after reviewing the principal assumptions believe the valuation is not materially different to the value as at the year end.

The deferred tax provision has made a full provision (at a rate of 25%) for the capital gains tax if the freehold properties were to be disposed of at these valuations.

Had the buildings not been re-valued, the comparable historical cost and depreciation values are as follows:

	2023 Freehold Properties £	2023 Investment Properties £	2022 Freehold Properties £	2022 Investment Properties £
Historical cost	29,544,248	16,575,496	23,291,398	16,434,804
Accumulated depreciation	(1,236,537)	-	(876,303)	-
At 31 March	<u>28,307,711</u>	<u>16,575,496</u>	<u>22,415,096</u>	<u>16,434,804</u>
Depreciation charge for the year	<u>361,663</u>	<u>-</u>	<u>281,470</u>	<u>-</u>

Company	Fixtures, Fittings & Equipment £	Motor Vehicles £	Total £
COST OR VALUATION			
At 1 April 2022	123,915	55,094	179,009
Additions	34,120	25,500	59,620
Disposals	(12,743)	-	(12,743)
At 31 March 2023	<u>145,292</u>	<u>80,594</u>	<u>225,886</u>
DEPRECIATION			
At 1 April 2022	66,485	45,611	112,096
Charge for the year	35,922	3,564	39,486
Disposals	(12,743)	-	(12,743)
At 31 March 2023	<u>89,664</u>	<u>49,175</u>	<u>138,839</u>
NET BOOK VALUE			
At 31 March 2023	<u>55,628</u>	<u>31,419</u>	<u>87,047</u>
At 31 March 2022	<u>57,430</u>	<u>9,483</u>	<u>66,913</u>

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

13. INVESTMENTS

Group

	Associated Undertakings £
Cost	
At 1 April 2022	37,500
Additions	9,299
At 1 April 2023	<u>46,799</u>
Uplift brought forward	450,200
Share of profit	57,553
Uplift carried forward	<u>507,753</u>
NET BOOK VALUE	
At 31 March 2023	<u>554,552</u>
At 31 March 2022	<u>487,700</u>

Company

	Subsidiary undertakings £	Associated Undertakings £	Total £
Cost or valuation			
At 1 April 2022	3,418,980	487,700	3,906,680
Share in the Profits	-	57,553	57,553
Additions	100	9,299	9,399
At 31 March 2023	<u>3,419,080</u>	<u>554,552</u>	<u>3,973,632</u>
Provision			
At 1 April 2022	-	-	-
Provision in the year	-	-	-
At 31 March 2023	<u>-</u>	<u>-</u>	<u>-</u>
At 31 March 2023	<u>3,419,080</u>	<u>554,552</u>	<u>3,973,632</u>
At 31 March 2022	<u>3,418,980</u>	<u>487,700</u>	<u>3,906,680</u>

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

13. INVESTMENTS (continued)

Subsidiary undertakings:

	Proportion of voting rights and shares held	Nature of business
Life Property Investments Limited	100%	Property letting
Life Property Construction Limited	100%	Property construction
Glenholme Specialist Healthcare (Holdings) Limited	100%	Divisional Holding Company
Glenholme Specialist Healthcare (Northern Region) Limited	100%	Learning, physical disability & psychiatric residential care and supported living
Glenholme Specialist Healthcare (Southern Region) Limited	100%	Learning & physical disability residential care and supported living
Glenholme Specialist Healthcare (Saltdean) Limited	100%	Learning & physical disability residential care and supported living
Glenholme Senior Living (Holdings) Limited	100%	Divisional Holding Company
Glenholme Senior Living (Sleaford) Limited	100%	Elderly residential care
Glenholme Senior Living (Vera James House) Limited	100%	Elderly residential care
Glenholme Senior Living (Spalding) Limited	100%	Elderly residential care
Glenholme Senior Living (Horncastle) Limited	100%	Elderly residential care
Glenholme Senior Living (March) Limited	100%	Elderly residential care
LPI (Northern) Limited	100%	Property letting

All the companies listed above are incorporated in England, the holding is in ordinary shares and have been included in the group consolidation. All companies listed above registered office is 79 High Street, Eton, Berks, SL4 6AF.

All the subsidiary undertakings are held by the company with the exception of Glenholme Senior Living (Vera James) Limited, Glenholme Senior Living (Spalding) Limited, Glenholme Senior Living (Horncastle) Limited, and Glenholme Senior Living (March) Limited which are owned by Glenholme Senior Living (Holdings) Limited and Glenholme Specialist Healthcare (Saltdean) Limited and LPI (Northern) Limited which are owned by Glenholme Specialist Healthcare (Holdings) Limited.

Associated undertakings all held by the group and company:

	Proportion of voting rights and shares held	Nature of business
Glenholme Wrightcare Limited	50%	Holding company
Glenholme Healthcare (Bispham Gardens) Limited	50%	Elderly residential care

All the associated companies listed above are incorporated in England, the holding in Glenholme Wrightcare Limited is in 'B' shares and in all other subsidiaries in ordinary shares and have been included in the group consolidation as associated undertakings. All companies listed above registered office is 79 High Street, Eton, Berks, SL46AF.

Glenholme Senior Living (Market Drayton) Limited and Wrightcare Construction Limited were dissolved during the year.

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

14. STOCKS

	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Finished goods	<u>20,288</u>	<u>10,739</u>	<u>-</u>	<u>-</u>

15. DEBTORS

	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Amounts due within one year:				
Trade debtors	1,592,731	976,689	-	-
Amounts owed by group undertakings	-	-	17,275,802	12,388,666
Amounts owed to related company	1,214,210	1,257,353	1,214,210	1,257,353
Other debtors	217,538	250,733	52,582	224,398
Director's loan	19,000	19,000	19,000	19,000
Prepayments and accrued income	326,065	383,931	33,727	31,791
	<u>3,369,544</u>	<u>2,887,706</u>	<u>18,595,321</u>	<u>13,921,208</u>
Amounts due after one year:				
Deferred tax	-	-	23,720	84,762
Amounts owed by group undertakings	-	-	8,545,420	8,305,052
Director's loan	133,833	151,250	133,833	151,250
Prepayments	254,000	119,039	-	-
	<u>387,833</u>	<u>270,289</u>	<u>8,702,973</u>	<u>8,541,064</u>

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

16. CREDITORS: Amounts falling due within one year

	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Bank loans and overdrafts	1,345,924	1,351,300	-	-
Trade creditors	1,086,443	1,115,917	313,684	439,510
Amounts owed to group undertakings	-	-	12,797,113	10,923,594
Other taxation and social security	518,827	390,993	425,858	312,543
Other creditors	1,203,545	932,959	973,366	763,408
Hire purchase obligations	-	3,586	-	3,586
Accruals and deferred income	1,515,830	1,048,075	359,797	376,856
	<u>5,670,569</u>	<u>4,842,830</u>	<u>14,869,818</u>	<u>12,819,497</u>

17. CREDITORS: Amounts falling due after more than one year

	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Bank loans and overdrafts	26,801,697	22,964,224	-	-
Hire purchase obligations	-	6,193	-	6,193
Other creditors	1,550,565	1,550,565	1,550,565	1,550,565
	<u>28,352,262</u>	<u>24,520,982</u>	<u>1,550,565</u>	<u>1,556,758</u>

Included in other creditors falling due after more than one year are £450,565 of directors loans. These are repayable at par on 30th April 2024 (subject to rights of early redemption and rights of conversion) and bear interest at 10% per annum and £1.1m of convertible loan notes which are repayable at par on 30th April 2024 (subject to rights of early redemption and rights of conversion) and bear interest at 10% per annum. The loan notes are secured on the assets of the holding company.

The bank loans are secured by charges over the assets of the group companies

Analysis of bank loans is as follows:

	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Due < 1 year	1,345,924	1,351,300	-	-
Due > 1 year and < 5 years	19,114,804	16,112,282	-	-
Due > 5 years	7,686,893	6,851,942	-	-
	<u>28,147,621</u>	<u>24,315,524</u>	<u>-</u>	<u>-</u>

The above comprises of loans that are repayment by instalments and that have differing interest rates ranging from 2.5% to 4% above bank base rate. The loans are repayable on a 20 year amortisation.

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

18. DEFERRED TAXATION

The movement in the deferred taxation provision during the year was:

	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Provision brought forward	2,592,707	874,152	(84,762)	(131,932)
Increase in provision profit and loss	588,846	664,093	61,042	47,170
Increase in provision revaluation reserve	468,941	1,054,462	-	-
Provision carried forward	<u>3,650,494</u>	<u>2,592,707</u>	<u>(23,720)</u>	<u>(84,762)</u>

The provision for deferred taxation consists of the tax effect of timing differences in respect of:

All provisions fully provided	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Excess of taxation allowances over depreciation on fixed assets	1,711,927	1,150,799	982	(10,803)
Other timing differences	(24,702)	(18,674)	(24,702)	(18,674)
On property revaluations	2,714,663	1,864,032	-	-
Less losses carried forward	(751,394)	(403,450)	-	(55,285)
	<u>3,650,494</u>	<u>2,592,707</u>	<u>(23,720)</u>	<u>(84,762)</u>

19. SHARE CAPITAL

Allotted, paid and called up:

	No	2023	No	2022
		£		£
Ordinary A shares of £0.01 each	13,646	136	13,646	136
Ordinary A investment shares of £0.01 each	6,482	65	6,482	65
Ordinary A-1 investment shares	4,473	45	4,473	45
	<u>24,601</u>	<u>246</u>	<u>24,601</u>	<u>246</u>

A shares and A-1 Ordinary shares have a priority right of redemption.

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

19. SHARE CAPITAL continued

The company has issued the following employee share options, the vesting period ending:

	Option price £771	Option price £1,156	2023 Option price £1,150	Option price £771	Option price £1,156	2022 Option price £1,150
Options with vesting period ending 15 Dec 2027	201	-	302	201	-	302
Options with vesting period ending 16 Sep 2029	200	300	-	200	300	-
	<u>401</u>	<u>300</u>	<u>302</u>	<u>401</u>	<u>300</u>	<u>302</u>

The options are for Ordinary shares at £0.01 a share.

20. RESERVES

Share Premium account – This reserve records the amount received for shares in excess of their issued value.

Revaluation reserve - This reserve records the unrealised gain on both tangible and investment properties. Revaluations on investment properties are first put through the profit and loss and then transferred to the revaluation reserve.

Profit and loss account - This reserve records retained earnings and accumulated losses.

21. OPERATING LEASES

The Group had the following total commitments under non-cancellable property operating leases:

	Group		Company	
	2023 £	2022 £	2023 £	2022 £
<1 year	2,600	2,600	-	-
Between 1 and 5 years	10,400	10,400	-	-
>5 years	278,200	280,800	-	-
	<u>291,200</u>	<u>293,800</u>	<u>-</u>	<u>-</u>

The above represents the ground rent on 10 leasehold flats for the 113 years remaining with an annual charge of £2,600

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

22. RELATED PARTY TRANSACTIONS

Group and Company

The company had the following convertible loan notes (on certain conditions) from directors and the balances are as follows:

	Due for repayment	Accrued interest as at 31 March 2023 not paid	Accrued interest as at 31 March 2022 not paid	Balance outstanding at 31 March 2023	Balance outstanding at 31 March 2022
		£	£	£	£
Aspen Property Services Limited (controlled by Kent Phippen, director)	Apr 24	-	-	375,000	375,000
JKHC Limited (controlled by Lord P Carter, director)	Apr 24	-	-	215,000	215,000
Lord P Carter or persons connected to Lord P Carter	Apr 24	-	-	33,000	33,000
Columbia Pacific Opportunity Fund LLP (32% shareholder)	Apr 24	-	-	355,000	355,000
Don Serratt (director)	Apr 24	-	-	-	-
Stuart McLaughlan (director) or connected person to Stuart McLaughlan	Apr 24	-	-	122,000	122,000
		-	-	1,100,000	1,100,000

The company had the following loan notes or loan agreements from directors and the balances are as follows:

Lord P Carter or persons connected to Lord P Carter	Apr 24	-	-	141,243	141,243
Aspen Property Services Limited (controlled by Kent Phippen, director)	Apr 24	-	-	209,322	209,322
Stuart McLaughlan (director) or connected person to Stuart McLaughlan	Apr 24	-	-	100,000	100,000
		-	-	450,565	450,565

The company rents a property from Aspen Property Services Limited for £36,000 excluding rates and insurance (2022: £36,000)

The company has taken advantage of the exemption provided by FRS102 Section 33.1A and has not disclosed transactions with other group companies where 100% of the voting rights are held within the group.

23. CAPITAL COMMITMENTS

	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Authorised but not committed	2,600,000	5,600,000	-	-
Committed	4,631,027	4,200,000	-	-

24. ULTIMATE CONTROLLING PARTY

There is no controlling party.

Glenholme
Group

GLENHOLME HEALTHCARE GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2023

25. PRINCIPAL SUBSIDIARY UNDERTAKINGS

Guaranteed under Section 479(A) of the Companies Act 2006:

Name	Holding	Proportion of voting rights and shares held	Company Number
Life Property Investments Ltd	Ordinary	100%	07250646
Life Property Construction Ltd	Ordinary	100%	11583481
Glenholme Specialist Healthcare (Holdings) Ltd	Ordinary	100%	13631430
Glenholme Specialist Healthcare (Northern Region) Ltd	Ordinary	100%	07446940
Glenholme Specialist Healthcare (Southern Region) Ltd	Ordinary	100%	05757165
Glenholme Senior Living (Holdings) Ltd	Ordinary	100%	12202234
Glenholme Senior Living (Sleaford) Ltd	Ordinary	100%	10015774
Glenholme Senior Living (Spalding) Ltd	Ordinary	100%	12204876
Glenholme Senior Living (Vera James House) Ltd	Ordinary	100%	12410875
Glenholme Senior Living (Horncastle) Ltd	Ordinary	100%	12760229
Glenholme Senior Living (March) Ltd	Ordinary	100%	12868165

26. DIRECTOR'S LOAN

	Group		Company	
	2023	2022	2023	2022
	£	£	£	£
Director's loan	152,833	170,250	152,833	170,250

The Director's loan is repayable over 10 years and is secured on the Director's shareholding. The maximum balance during the year was £170,250 (2022 £175,000) and Interest is charged at 1% over bank base rate.